Dynamic coupling of whole-brain neuronal and neurotransmitter systems Morten L. Kringelbach, Josephine Cruzat, Joana Cabral, Gitte Moos Knudsen, Robin Carhart-Harris, Peter C. Whybrow Nikos K. Logothetis, and Gustavo Deco PNAS, 2020, 1-11 doi : 10.1073/pnas.1921475117 Remarkable progress has come from whole-brain models linking anatomy and function. Paradoxically, it is not clear how a neuronal dynamical system running in the fixed human anatomical connectome can give rise to the rich changes in the functional repertoire associated with human brain function, which is impossible to explain through long-term plasticity. Neuromodulation evolved to allow for such flexibility by dynamically updating the effectivity of the fixed anatomical connectivity. [...]
Lire la suiteAn epidemiological, developmental and clinical overview of cannabis use during pregnancy Hanan El Marroun, Qiana L. Brown, Ingunn Olea Lund, Victoria H. Coleman-Cowger, Amy M. Loree, Devika Chawlaj, Yukiko Washio Preventive Medicine, 2018, 116, 1–5 Doi : 10.1016/j.ypmed.2018.08.036 A B S T R A C T The objective of the current narrative literature review is to provide an epidemiological, developmental and clinical overview on cannabis use during pregnancy. Cannabis use in pregnancy poses major health concerns for pregnant mothers and their developing children. Although studies on the short- and long-term consequences of prenatal cannabis exposure are increasing, findings have been inconsistent or difficult to interpret [...]
Lire la suiteThe Broad Concept of “Spasticity- Plus Syndrome” in Multiple Sclerosis : A Possible New Concept in the Management of Multiple Sclerosis Symptoms Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto and Lluis Ramió Frontiers in Neurology , 2020 | Volume 11 | Article 152 doi : 10.3389/fneur.2020.00152 Multiple sclerosis (MS) pathology progressively affects multiple central nervous system (CNS) areas. Due to this fact, MS produces a wide array of symptoms. Symptomatic therapy of one MS symptom can cause or worsen other unwanted symptoms (anticholinergics used for bladder dysfunction produce impairment of cognition, many MS drugs produce erectile dysfunction, etc.). Appropriate symptomatic [...]
Lire la suiteTerpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors David B. Finlay, Kathleen J. Sircombe, Mhairi Nimick, Callum Jones and Michelle Glass Frontiers in Pharmacology, 2020, Volume 11, Article 359, 1-9. doi : 10.3389/fphar.2020.00359 The entourage effect was a proposed explanation for biological observations that endocannabinoid ligand activities can be modified by other lipids released from cells at the same time. An increasing volume of anecdotal reports and interest in the plant have provoked research into the activity of minor chemical constituents of the plant—including volatile terpenoids such as myrcene, a- and b- pinene, b-caryophyllene, and limonene. However, to [...]
Lire la suiteHigh Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity Marie Fitzgibbon, David P. Finn, Michelle Roche International Journal of Neuropsychopharmacology, 2016, 19, (3), 1–20 doi : 10.1093/ijnp/pyv095 Abstract Depression and pain are two of the most debilitating disorders worldwide and have an estimate co-occurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired healthrelated quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation [...]
Lire la suiteCannabinoids Rescue Cocaine-Induced Seizures by Restoring Brain Glycine Receptor Dysfunction Guichang Zou, Xin Zuo, Kai Chen, ..., Guangming Huang, Dan Liu, Wei Xiong Cell Reports, 2020, 30, 4209–4219 Doi : 10.1016/j.celrep.2020.02.106 In Brief Zou et al. identify the glycine receptor as a potential therapeutic target for cannabinoids in treating cocaine-induced seizures. The function of extra-synaptic glycine receptors in the prefrontal cortex and hippocampus is impaired by cocaine and rescued by cannabinoids, therefore leading to the therapeutic effects of cannabinoids in treating cocaine-induced seizures. Highlights Cannabinoids alleviate cocaine-induced seizures (CISs) by glycine receptors (GlyRs) Cannabinoid docking reduces hydrogen-bonding interaction between cocaine and GlyRs The prefrontal cortex and hippocampus [...]
Lire la suiteCannabis use and the course and outcome of major depressive disorder : A population based longitudinal study FEINGOLD D., REHM J., LEV-RAN S. Psychiatry Research, 2017, 251, 225-234. Doi : 10.1016/j.psychres.2017.02.027 Highlights • Individuals with baseline major depressive disorder were followed over a three-year time period. • Cannabis users and individuals with cannabis use disorders were compared to nonusers. • No differences were found in rates of remission between the groups. • Level of cannabis use was associated with significantly more depressive symptoms at follow-up. • These findings did not retain significance after adjusting for baseline confounding factors. Abstract Cannabis use has been reported to affect [...]
Lire la suiteCannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia Fernanda F. Peres, Mariana C. Diana, Raquel Levin, Mayra A. Suiama, Valéria Almeida, Ana M. Vendramini, Camila M. Santos, Antônio W. Zuardi, Jaime E. C. Hallak, José A. Crippa and Vanessa C. Abílio Frontiers in Pharmacology, 2018, 9, article 901. Doi : 10.3389/fphar.2018.00901 Schizophrenia is considered a debilitating neurodevelopmental psychiatric disorder and its pharmacotherapy remains problematic without recent major advances. The development of interventions able to prevent the emergence of schizophrenia would therefore represent an enormous progress. Here, we investigated whether treatment with cannabidiol (CBD – a compound of Cannabis sativa that [...]
Lire la suiteBibliographie : Cannabinoïdes et Douleurs Docteur Christian Sueur, GRECC, avril 2020 1 – Cannabinoïdes et douleurs : 1 - 4 2 - Cannabinoïdes et douleurs aigües : 5 3 – Cannabinoïdes et douleurs chroniques (non-cancéreuses) : 6 - 8 4 - Cannabinoïdes et douleurs neuropathiques : 9 - 12 5 - Cannabinoïdes et douleurs cancéreuses : 13 – 15 6 - Cannabinoïdes et « alternatives » aux opiacés : 16 - 17
Lire la suiteBIBLIOGRAPHIE : Système endocannabinoïdes et récepteurs aux cannabinoïdes Dr Christian Sueur, GRECC, avril 2020. 1 - Système endocannabinoïde : 1 - 7 2 - Récepteurs des cannabinoïdes : 8 - 13 3 - THC et récepteurs non-cannabinoïdes : 14 4 - CBD et récepteurs non cannabinoïdes : 15 5 - Neurophysiologie des endocannabinoïdes : 16 - 19 6 - Neuropharmacologie des cannabinoïdes de synthèse : 20 - 21 7 - Neuropharmacologie des Phytocannabinoïdes : 22 - 29
Lire la suite